<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02734706</url>
  </required_header>
  <id_info>
    <org_study_id>15LCHU</org_study_id>
    <nct_id>NCT02734706</nct_id>
  </id_info>
  <brief_title>Efficacy of a LRC™ (L. Reuteri NCIMB 30242) Capsule on Managing Cholesterol in Adults</brief_title>
  <official_title>Efficacy of a Supplement Capsule Containing LRC™ (L. Reuteri NCIMB 30242) on Managing Cholesterol Levels in Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UAS Labs LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UAS Labs LLC</source>
  <brief_summary>
    <textblock>
      To investigate the effect of a supplement capsule containing LRC™ (L. reuteri NCIMB 30242),
      taken twice daily with lunch and dinner (NLT 2.5E9 CFU per dose), versus placebo capsule on
      serum low density lipoprotein (LDL)-cholesterol in otherwise healthy hypercholesterolemic
      adults after 9 weeks of product consumption.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum LDL-cholesterol after 9 weeks of product consumption.</measure>
    <time_frame>9 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum LDL-cholesterol after 6 weeks of product consumption.</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum total cholesterol after 6 and 9 weeks of product consumption.</measure>
    <time_frame>6 and 9 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum HDL-cholesterol after 6 and 9 weeks of product consumption.</measure>
    <time_frame>6 and 9 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum non-HDL-cholesterol after 6 and 9 weeks of product consumption.</measure>
    <time_frame>6 and 9 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum triglycerides after 6 and 9 weeks of product consumption.</measure>
    <time_frame>6 and 9 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum apolipoprotein B-100 after 6 and 9 weeks of product consumption.</measure>
    <time_frame>6 and 9 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum hs-CRP after 9 weeks of product consumption.</measure>
    <time_frame>9 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma fibrinogen after 9 weeks of product consumption.</measure>
    <time_frame>9 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma homocysteine after 9 weeks of product consumption.</measure>
    <time_frame>9 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GI health questionnaire score after 6 and 9 weeks of product consumption.</measure>
    <time_frame>6 and 9 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>LRC™ capsule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo capsule</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>LRC™ capsule</intervention_name>
    <description>Twice per day (BID), 9 weeks</description>
    <arm_group_label>LRC™ capsule</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo capsule</intervention_name>
    <description>Twice per day (BID), 9 weeks</description>
    <arm_group_label>Placebo capsule</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females aged 20 to 75 years.

          -  LDL-C ≥ 3.40 mmol/L at visits V0 and V2-1 (&lt;15% variation between visits V0 and V2-1).

          -  TG &lt; 4.00 mmol/L (checked at visits V0 and V2-1).

          -  BMI between 23.0 to 32.5 kg/m2.

          -  Subject understands and accepts to follow the dietary recommendations advisable for
             hypercholesterolemic patients (according to NCEP-ATP III guidelines)

          -  Judged by the investigators as compliant (&gt;80%) with product consumption (check at
             V2-1), and motivated.

          -  Subjects taking stable doses of thyroid hormone and anti-hypertensive agents will be
             permitted, as long as these are continued equivalently throughout the duration of
             study.

          -  Agreement to maintain current level of physical activity throughout the study.

          -  If female, subject is not of child bearing potential. Defined as females who have had
             a hysterectomy or oophorectomy, bilateral tubal ligation or are post-menopausal
             (natural or surgically with &gt; 1 year since last menstruation) OR Female subject of
             childbearing potential must agree to use a medically approved method of birth control
             and have a negative urine pregnancy test result. Acceptable methods of birth control
             include Hormonal contraceptives including oral contraceptives, hormone birth control
             patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives
             (Depo-Provera, Lunelle), or hormone implant (Norplant System); Intrauterine devices;
             Vasectomy of partner.

          -  Voluntary, written, informed consent to participate in the study.

        Exclusion Criteria:

          -  Use of cholesterol lowering prescription drugs within the last 6 months.

          -  Use of plant sterols, omega 3, fish oil, soy protein, soluble oat fiber, psyllium seed
             husk, or other cholesterol lowering non-prescription supplements within last 1 month.

          -  History of chronic use of alcohol (&gt;2 drinks/d).

          -  History of heavy smoking (≥20 cigarettes/d).

          -  Use of systemic antibodies, corticosteroids, androgens, or phenytoin.

          -  Immune-compromised subjects (e.g. AIDS, lymphoma, subjects undergoing long-term
             corticosteroid treatment).

          -  Subject having experienced any cardiovascular event (myocardial infarction, coronary
             artery bypass, or other major surgical procedures) in the last 6 months.

          -  Subjects with elevated LDL-C (≥ 3.40 mmol/L) and high (&gt;20%) CVD risk estimated by the
             Framingham risk score.

          -  Previously diagnosed Type I or Type II diabetes or any other endocrine disorders such
             as adrenal insufficiency, Cushing's disease, hyperthyroidism, hypopituitarism or
             polycystic ovary syndrome.

          -  Subject receiving systemic treatment or topical treatment likely to interfere with
             evaluation of the study parameters.

          -  Subject currently involved in a clinical trial or in an exclusion period following
             participation in another clinical trial.

          -  History of angina, congestive heart failure, inflammatory bowel disease, pancreatitis,
             gastrointestinal, renal, pulmonary, hepatic or biliary disease, or cancer (evidence of
             active lesions, chemotherapy or surgery in the past year).

          -  Clinically significant abnormal laboratory results at screening.

          -  Chronic user of probiotics or fibre laxative (greater than 2 doses/wk), or stimulant
             laxatives.

          -  History of eating disorders.

          -  Exercise greater than 15 miles/wk or 4,000 kcal/wk.

          -  For female subjects: Pregnancy, breast feeding, or intent to get pregnant.

          -  Allergy or sensitivity to test product ingredients.

          -  Allergy or sensitivity to all 3 antibiotics (Clindamycin, Erythromycin and
             Ampicillin).

          -  Diagnosis of anemia or bleeding disorders
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mal Evans, PhD</last_name>
    <email>mevans@kgksynergize.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>KGK Synergize Inc.</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5R8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mal Evans, PhD</last_name>
      <email>mevans@kgksynergize.com</email>
    </contact>
    <investigator>
      <last_name>Tetyana Pelipyagina, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2016</study_first_submitted>
  <study_first_submitted_qc>April 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 12, 2016</study_first_posted>
  <last_update_submitted>April 27, 2018</last_update_submitted>
  <last_update_submitted_qc>April 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

